BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33812696)

  • 1. Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Geoffron S; Lier A; de Kermadec E; Sermondade N; Varinot J; Thomassin-Naggara I; Bendifallah S; Daraï E; Chabbert-Buffet N; Kolanska K
    Gynecol Oncol; 2021 Jun; 161(3):817-824. PubMed ID: 33812696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
    Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
    Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study.
    Delattre S; Segers I; Van Moer E; Drakopoulos P; Mateizel I; Enghels L; Tournaye H; De Vos M
    Hum Reprod; 2020 Nov; 35(11):2524-2536. PubMed ID: 32951035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fertility preservation after fertility-sparing surgery in women with borderline ovarian tumours.
    Khiat S; Provansal M; Bottin P; Saias-Magnan J; Metzler-Guillemain C; Courbiere B
    Eur J Obstet Gynecol Reprod Biol; 2020 Oct; 253():65-70. PubMed ID: 32784054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
    Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
    Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
    Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
    Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Therapeutic Management of Early Stages].
    Canlorbe G; Lecointre L; Chauvet P; Azaïs H; Fauvet R; Uzan C
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):287-303. PubMed ID: 32004786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
    Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
    Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
    Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
    Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response.
    Alvarez RM; Ramanathan P
    Hum Reprod; 2018 Nov; 33(11):2051-2059. PubMed ID: 27370358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epithelial ovarian cancer and fertility preservation: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Uzan C; Courbiere B; Chabbert-Buffet N
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):180-186. PubMed ID: 30704956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive outcomes in women opting for fertility preservation after fertility-sparing surgery for borderline ovarian tumors.
    Cosyns S; Van Moer E; De Quick I; Tournaye H; De Vos M
    Arch Gynecol Obstet; 2024 May; 309(5):2143-2152. PubMed ID: 38494510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Fertility].
    Raad J; Rolland L; Grynberg M; Courbiere B; Mathieu d'Argent E
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):330-336. PubMed ID: 32004782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian response to stimulation for fertility preservation in women with hematologic cancer.
    Brun T; Dion L; Jaillard S; Bales D; Domin M; Lavoué V; Levêque J; Houot R; Duros S
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101925. PubMed ID: 33010467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors.
    Helpman L; Beiner ME; Aviel-Ronen S; Perri T; Hogen L; Jakobson-Setton A; Ben-Baruch G; Korach J
    Fertil Steril; 2015 Jul; 104(1):138-44. PubMed ID: 25956371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elective and Onco-fertility preservation: factors related to IVF outcomes.
    Cobo A; García-Velasco J; Domingo J; Pellicer A; Remohí J
    Hum Reprod; 2018 Dec; 33(12):2222-2231. PubMed ID: 30383235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
    Rousset-Jablonski C; Selle F; Adda-Herzog E; Planchamp F; Selleret L; Pomel C; Chabbert-Buffet N; Daraï E; Pautier P; Trémollières F; Guyon F; Rouzier R; Laurence V; Chopin N; Faure-Conter C; Bentivegna E; Vacher-Lavenu MC; Lhomme C; Floquet A; Treilleux I; Lecuru F; Gouy S; Kalbacher E; Genestie C; de la Motte Rouge T; Ferron G; Devouassoux-Shisheboran M; Kurtz JE; Namer M; Joly F; Pujade-Lauraine E; Grynberg M; Querleu D; Morice P; Gompel A; Ray-Coquard I
    Bull Cancer; 2018 Mar; 105(3):299-314. PubMed ID: 29397916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes.
    Segers I; Bardhi E; Mateizel I; Van Moer E; Schots R; Verheyen G; Tournaye H; De Vos M
    Hum Reprod; 2020 Sep; 35(9):2026-2036. PubMed ID: 32829388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility preservation in borderline ovarian tumor patients and survivors.
    Poulain M; Vandame J; Tran C; Koutchinsky S; Pirtea P; Ayoubi JM
    Horm Mol Biol Clin Investig; 2020 Jul; 43(2):179-186. PubMed ID: 32628631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.